These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 26941473)
21. Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer. Ong CHC; Lee DY; Lee B; Li H; Lim JCT; Lim JX; Yeong JPS; Lau HY; Thike AA; Tan PH; Iqbal J Breast Cancer Res; 2022 Jun; 24(1):38. PubMed ID: 35659359 [TBL] [Abstract][Full Text] [Related]
22. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385 [TBL] [Abstract][Full Text] [Related]
23. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. McIntyre A; Patiar S; Wigfield S; Li JL; Ledaki I; Turley H; Leek R; Snell C; Gatter K; Sly WS; Vaughan-Jones RD; Swietach P; Harris AL Clin Cancer Res; 2012 Jun; 18(11):3100-11. PubMed ID: 22498007 [TBL] [Abstract][Full Text] [Related]
24. Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells. Li Y; Wang H; Oosterwijk E; Tu C; Shiverick KT; Silverman DN; Frost SC Cancer Invest; 2009 Jul; 27(6):613-23. PubMed ID: 19367501 [TBL] [Abstract][Full Text] [Related]
25. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Zhou GX; Ireland J; Rayman P; Finke J; Zhou M Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243 [TBL] [Abstract][Full Text] [Related]
26. Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cells. Li Y; Tu C; Wang H; Silverman DN; Frost SC J Biol Chem; 2011 May; 286(18):15789-96. PubMed ID: 21454639 [TBL] [Abstract][Full Text] [Related]
27. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Tan EY; Yan M; Campo L; Han C; Takano E; Turley H; Candiloro I; Pezzella F; Gatter KC; Millar EK; O'Toole SA; McNeil CM; Crea P; Segara D; Sutherland RL; Harris AL; Fox SB Br J Cancer; 2009 Jan; 100(2):405-11. PubMed ID: 19165203 [TBL] [Abstract][Full Text] [Related]
28. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Robertson N; Potter C; Harris AL Cancer Res; 2004 Sep; 64(17):6160-5. PubMed ID: 15342400 [TBL] [Abstract][Full Text] [Related]
29. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780 [TBL] [Abstract][Full Text] [Related]
30. Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells. Zandberga E; Zayakin P; Ābols A; Pūpola D; Trapencieris P; Linē A Cancer Biol Ther; 2017 Aug; 18(8):596-605. PubMed ID: 28665755 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. Janning M; Müller V; Vettorazzi E; Cubas-Cordova M; Gensch V; Ben-Batalla I; Zu Eulenburg C; Schem C; Fasching PA; Schnappauf B; Karn T; Fehm T; Just M; Kühn T; Holms F; Overkamp F; Krabisch P; Rack B; Denkert C; Untch M; Tesch H; Rezai M; Kittel K; Pantel K; Bokemeyer C; Loibl S; von Minckwitz G; Loges S Int J Cancer; 2019 Aug; 145(3):857-868. PubMed ID: 30694523 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy. Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Kappler M; Taubert H; Holzhausen HJ; Reddemann R; Rot S; Becker A; Kuhnt T; Dellas K; Dunst J; Vordermark D; Hänsgen G; Bache M Strahlenther Onkol; 2008 Aug; 184(8):393-9. PubMed ID: 18956515 [TBL] [Abstract][Full Text] [Related]
34. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453 [TBL] [Abstract][Full Text] [Related]
35. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Betof AS; Rabbani ZN; Hardee ME; Kim SJ; Broadwater G; Bentley RC; Snyder SA; Vujaskovic Z; Oosterwijk E; Harris LN; Horton JK; Dewhirst MW; Blackwell KL Br J Cancer; 2012 Feb; 106(5):916-22. PubMed ID: 22333602 [TBL] [Abstract][Full Text] [Related]
36. The relationship between carbonic anhydrase IX (CAIX) and patient survival in breast cancer: systematic review and meta-analysis. Shamis SAK; Edwards J; McMillan DC Diagn Pathol; 2023 Apr; 18(1):46. PubMed ID: 37061698 [TBL] [Abstract][Full Text] [Related]
37. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582 [TBL] [Abstract][Full Text] [Related]
38. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622 [TBL] [Abstract][Full Text] [Related]
39. Role of zinc in catalytic activity of carbonic anhydrase IX. Tu C; Foster L; Alvarado A; McKenna R; Silverman DN; Frost SC Arch Biochem Biophys; 2012 May; 521(1-2):90-4. PubMed ID: 22465027 [TBL] [Abstract][Full Text] [Related]
40. Targeting angiogenesis in metastatic breast cancer. Reddy S; Raffin M; Kaklamani V Oncologist; 2012; 17(8):1014-26. PubMed ID: 22843553 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]